A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Tareq Al Baghdadi et al.|Clinical Cancer Research|2020Cited by 326
Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated RadiotherapyHale Başak Çağlar, Aaron M. Allen, Roy B. Tishler et al.|International Journal of Radiation Oncology*Biology*Physics|2008Cited by 230
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterRoland B. Walter, Elihu H. Estey, Megan Othus et al.|Leukemia|2014Cited by 172
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Razelle Kurzrock, Megan Othus, Sandip Pravin Patel et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 159
A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant LesionsLori J. Wirth, Monica M. Bertagnolli, Yi Li et al.|Cancer Prevention Research|2008Cited by 29